Gene Therapy

DNA May Predict Benefit of Lung Cancer Treatment (3/15/07)

A genetic test holds promise for identifying which early-stage lung cancer patients would benefit from chemotherapy and which would be better off without it, researchers report.

The test might also work in a similar way for patients with other malignancies, the experts said. More...

High Tech Detectives Screen Thousands Of Genes, Proteins To Solve Puzzle Of Lung Disease (10/23/06)

Recent advances in computer and imaging technology allow the scanning of tens of thousands of genes and proteins in little more than a blink of an eye. This high speed technology has already produced advances in the understanding of disease, including lung disease, and the already blistering pace is picking up. More...

Gene Signature Could Revolutionize Cancer Care (6/3/05)

Scientists have identified an 11-gene "signature" in cancer tumors that appears to predict prognosis in at least 10 types of malignancies. If it passes further testing, the signature may help doctors and patients decide on therapies that suit particular cancer types, a giant step forward in the emerging era of tailored treatments. More...

Australians Prepare for mesothelioma Epidemic with Breakthrough Diagnostic Test (9/16/03)

Melbourne researchers have achieved a breakthrough that promises to significantly improve the treatment of people with asbestos-related cancer, which is tipped to reach epidemic proportions in a decade. More...

MG98's Preclinical Antitumor Activity and Safety, and Phase 1 Clinical Profile Demonstrated in Two Mesothelioma Patients (11/2/01)

MG98 is a second-generation antisense oligonucleotide that inhibits the enzyme DNA methyltransferase. More...

Preclinical Data of Introgen's INGN 241 Demonstrate Broad Anti-Cancer Activity In Multiple Tumor Types as Monotherapy and in Combination; Update on Gene Therapy Research at MDA under Dr. Roy Smythe. (6/14/01)

Introgen Therapeutics, Inc. today reported preclinical findings demonstrating that INGN 241, an Adenoviral vector encoding the mda-7 gene, is a novel cytokine family member that exhibits broad anticancer activity. More...

Australia Doctors: Gene Therapy (IL-12) Retards Mesothelioma in Mice But Causes Side Effects (9/27/99)

Gene therapy that boosts the body's immune system appears to be effective at preventing mesothelioma -- a lethal tumor of the lining of the chest -- from growing in mice, according to Australian researchers. More...

Brave 49 Year Old Woman Shows Response to Gene Therapy, But Tumors Return. New Orleans, LA (8/3/99)

Patricia Johnson is a 49 year old woman who was diagnosed with mesothelioma in August of 1998. She lives in New Orleans, Louisiana. Her doctor is Dr. Paul Schwarzenberger, who is the principal investigator of the Gene Therapy Program at the Louisiana State University Medical Center in New Orleans. More...

Antitumor Activity With Gene Modified Tumor Cells: Dr. Paul Schwarzenberger (8/14/98)

Since it is uniformly fatal and kills by local spread, investigators have proposed that malignant mesotthelioma is a good target for novel treatment approaches, such as gene therapy. More...

Son of Insulator with MM Helps Father Enroll in Gene Therapy Program at LSU. New Orleans, LA (12/10/97)

My name is Todd Armstrong. On February 24th, 1997, my Dad, Bill Armstrong, was diagnosed with malignant mesothelioma (M.M.). I wanted to try to help my dad find some treatment for this, so I started looking on the Internet. More...

Gene Therapy Phase I Study at LSU Medical Center: Dr. Paul Schwarzenberger (12/97)

Because of the dismal prognosis for patients with malignant mesothelioma, a new mode of treatment is desperately needed. A promising area of research into the treatment of various malignancies is gene therapy. More...

University of Pennsylvania Study

(1996) The University of Pennsylvania in Philadelphia has developed a new "gene therapy" protocol that is designed to weaken the tumor cells. In the first phase, the patient takes biopsy samples from the lung and places a tube into the chest cavity near the tumors.

Click here for A Conversation Between Roger G. Worthington and Dr. Daniel Sterman - August 20th, 1996 Regarding: The ongoing clinical trials at the University of Pennsylvania